EcoDrugPlus

Histone Deacetylase 11

Ensembl ID : ENSDCDG00000028598
Gene Symbol: HDAC11
3 Cross references
200 Possible Orthologues:

Histone Deacetylase 2

Ensembl ID : ENSDCDG00000021144
Gene Symbol: HDAC2
3 Cross references
205 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSDCDG00000014871
Gene Symbol: HDAC4
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 4-Like

Ensembl ID : ENSDCDG00000033249
Gene Symbol: LOC114764501
2 Cross references
196 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSDCDG00000012071
Gene Symbol: HDAC5
3 Cross references
195 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSDCDG00000030973
Gene Symbol: HDAC5
3 Cross references
195 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSDCDG00000008185
Gene Symbol: HDAC6
3 Cross references
182 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSDCDG00000026829
Gene Symbol: HDAC7
3 Cross references
197 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSDCDG00000004541
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2-Like

Ensembl ID : ENSDCDG00000003544
Gene Symbol: LOC114771726
2 Cross references
237 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSDCDG00000034942
Gene Symbol: HCN4
3 Cross references
211 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSDCDG00000023997
Gene Symbol: HCN4
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).